Stockreport

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consort...

MediciNova, Inc.  (MNOV) 
Last medicinova, inc. earnings: 4/23 04:20 pm Check Earnings Report
US:NASDAQ Investor Relations: medicinova.com/investor-relations/media-archive
PDF LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Mar [Read more]